Blog
RSS FeedPosted by Michael Wonder on 11 Mar 2023
Drug pricing throughout the product lifecycle: a work in progress
10 March 2023 - Increases in drug prices and drug spending are of concern to health systems worldwide. This has naturally ...
Posted by Michael Wonder on 01 Mar 2023
ICER publishes evidence report on lecanemab for Alzheimer’s disease
1 March 2023 - Currently available evidence is rated as promising but inconclusive to determine whether lecanemab provides a net health ...
Posted by Michael Wonder on 21 Feb 2023
ICER publishes final evidence report on treatments for multiple sclerosis
21 February 2023 - Independent appraisal committee voted that evidence is not adequate to demonstrate a superior net health benefit ...
Posted by Michael Wonder on 16 Feb 2023
ICER releases draft evidence report on treatments for non-alcoholic steatohepatitis
16 February 2023 - The ICER today released a draft evidence report assessing the comparative clinical effectiveness and value of resmetirom ...
Posted by Michael Wonder on 23 Jan 2023
ICER publishes final evidence report on fezolinetant for vasomotor symptoms associated with menopause
23 January 2023 - Independent appraisal committee voted that evidence is not yet adequate to demonstrate a net health benefit ...
Posted by Michael Wonder on 17 Jan 2023
ICER publishes second annual assessment of barriers to fair access within US commercial insurance prescription drug coverage
17 January 2023 - During ICER’s assessment, five payers revised policies for 11 medicines in ways that bring coverage into ...
Posted by Michael Wonder on 22 Dec 2022
ICER releases draft evidence report on treatments for Alzheimer’s disease
22 December 2022 - Registration now open for 5 January “Early Insights” webinar. ...
Posted by Michael Wonder on 21 Dec 2022
ICER publishes evidence report on treatments for multiple sclerosis
21 December 2022 - Evidence is rated as insufficient to differentiate the net health benefit between ublituximab and other monoclonal antibodies; ...
Posted by Michael Wonder on 20 Dec 2022
ICER provides update on value based pricing of Paxlovid as an outpatient treatment for COVID-19
20 December 2022 - New data suggests Paxlovid will achieve common thresholds of cost effectiveness if priced between $563-$906 per treatment ...
Posted by Michael Wonder on 01 Dec 2022
ICER publishes evidence report on fezolinetant for vasomotor symptoms associated with menopause
1 December 2022 - Evidence is rated as promising but inconclusive to determine whether fezolinetant provides a net health benefit for ...
Posted by Michael Wonder on 22 Oct 2022
Patient centred health technology assessment: a perspective on engagement in health technology assessment by three patient organisations and a health technology assessment body
20 October 2022 - Patient engagement in health technology assessment has become increasingly important over the past 20 years. ...
Posted by Michael Wonder on 20 Oct 2022
ICER publishes final evidence report and policy recommendations on treatments for obesity management
20 October 2022 - Independent appraisal committee voted that evidence is adequate to demonstrate that semaglutide provides a net health benefit ...
Posted by Michael Wonder on 20 Oct 2022
ICER evaluates drug price increases in California
20 October 2022 - Unsupported Price Increase” final report based on drugs identified through SB-17, the California drug price transparency law. ...
Posted by Michael Wonder on 17 Oct 2022
Can state prescription drug affordability boards address high cost drug prices?
11 October 2022 - State law makers, like their federal counterparts, are focused on addressing the high and growing cost of ...
Posted by Michael Wonder on 17 Oct 2022
ICER releases draft evidence report on treatments for multiple sclerosis
17 October 2022 - Public comment period now open until 11 November 2022; requests to make oral comment during public ...